CEBPA and neoplasm: Interestingly, both ATRA and EP300 inhibitor A-485 could decrease TRIM71 and CEBPA expression and dampen glycine/serine metabolism, and ATRA could enhance anti-tumor ability of A-485 in liver cancer.